Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholestasis: therapeutic options]

U Beuers1, M Oswald

  • 1Medizinische Klinik II, Klinikum Grosshadern der LMU München.

Therapeutische Umschau. Revue Therapeutique
|April 18, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.

The Journal of antimicrobial chemotherapy·2024
Same author

Doppler follow-up after TIPS placement is not routinely indicated. A 16-years single centre experience.

The Netherlands journal of medicine·2020
Same author

[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].

Der Radiologe·2019
Same author

[IgG4-associated cholangitis - clinical presentation of an overlooked disease entity].

Der Internist·2018
Same author

[SaO<sub>2</sub> and PaO<sub>2</sub> mismatch: Do not forget hemoglobinopathy].

Revue des maladies respiratoires·2018
Same author

[Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Der Internist·2017
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Ursodeoxycholic acid (UDCA) is an effective treatment for primary biliary cirrhosis and other cholestatic liver diseases. While liver transplantation is used for end-stage conditions, UDCA offers a well-tolerated therapeutic option for managing cholestasis symptoms.

Area of Science:

  • Hepatology and Gastroenterology
  • Pharmacology and Therapeutics

Context:

  • Primary biliary cirrhosis (PBC) is a model chronic cholestatic liver disease.
  • Ursodeoxycholic acid (UDCA) demonstrates efficacy and tolerability in PBC management.
  • Cholestatic disorders encompass conditions like primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy.

Purpose:

  • To review the therapeutic applications of Ursodeoxycholic acid (UDCA) in cholestatic liver diseases.
  • To highlight the role of UDCA in managing symptoms associated with chronic cholestasis.

Summary:

  • Ursodeoxycholic acid (UDCA) is a well-established treatment for primary biliary cirrhosis.
  • UDCA's benefits extend to other cholestatic conditions, including primary sclerosing cholangitis, cystic fibrosis, and intrahepatic cholestasis of pregnancy.

Related Experiment Videos

  • While liver transplantation remains the definitive treatment for end-stage disease, symptomatic management of cholestasis-associated issues like pruritus, osteopathy, and vitamin deficiency is crucial.

    • Impact:

    • UDCA provides a valuable therapeutic option for patients with chronic cholestatic liver diseases.
    • Understanding UDCA's role aids in optimizing patient care and managing disease complications.
    • This review underscores the importance of pharmacotherapy in alleviating symptoms and improving outcomes in cholestatic conditions.